Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
India Busts Another Western Drug Patent
by Jean-François Tremblay
November 12, 2012
| A version of this story appeared in
Volume 90, Issue 46
India’s Intellectual Property Appellate Board has sided with a local nonprofit organization and decided that Roche’s patent on the hepatitis drug Pegasys is not valid in India. The board’s decision reverses a 2007 ruling by the Controller General of Patents, Designs & Trademarks. The appellate board explained that the Roche drug lacks inventiveness because anyone familiar with the scientific literature when Roche patented it could have invented an identical treatment. Known generically as PEGylated interferon alfa-2a, Pegasys is an antiviral that uses polyethylene glycol to enhance the half-life of interferon.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter